Source – Sanofi
On June 29, 2023, Sanofi is hosting an investor event focused on its Vaccines pipeline, featuring key leaders from the company. The event aims to highlight how Sanofi’s strategy is supported by its research and development (R&D) efforts in the field of vaccines. Over the past few years, Sanofi has strategically reinvested in key growth drivers and revitalized its pipeline, positioning itself favorably as it enters the second phase of its Play to Win strategy.
The vaccines business at Sanofi is poised for sustained growth, driven by core franchises such as influenza, meningitis, and pediatric vaccines. The company has further strengthened its portfolio with a best-in-class Respiratory Syncytial Virus (RSV) franchise, targeting protection for infants, toddlers, and older adults. Sanofi has made significant progress in enhancing its vaccines R&D capabilities, including the rapid development of an advanced mRNA platform, coupled with extensive industrial and commercial expertise worldwide.
“Today, we’re pleased to showcase how vaccine R&D is significantly contributing to the continued growth of the company through the design, development, and delivery of vaccines that address unmet needs. The pace of our innovation is buoyed both by a sense of urgency to address existing public health needs at multiple stages in life, and by our continued transformation as a company that simply won’t accept ‘good enough.”
– Thomas Triomphe, Executive Vice President, Vaccines, Sanofi
Within a short span of two years, Sanofi has successfully developed a competitive mRNA platform that exhibits improved potency and thermostability, demonstrating efficacy against both viral and bacterial targets. Leveraging a robust internal and external innovation ecosystem, Sanofi’s mRNA Center of Excellence has accelerated the advancement of mRNA technology, including enhancements in lipid nanoparticles.
“With the addition of mRNA, we now have the largest development toolbox in the industry. This allows us to tackle public health challenges like RSV across multiple stages of life, applying the right platform to the right age group. Adding machine learning and antigen design means that our future vaccines will raise the bar beyond today’s high standards. With a clear focus on delivering only first- and best-in-class vaccines, we’re wholly focused on innovative R&D and flawless execution.”
– Jean-François Toussaint, Global Head of Vaccines R&D, Sanofi
During the event, Sanofi will present the latest data from its RSV development program, including the Phase IIIb HARMONIE data for Beyfortus (nirsevimab), designed to provide comprehensive protection against RSV for infants in their first season. Additionally, positive Phase I/II results will be shared for the RSV vaccine intended for toddlers (SP0125) and the RSV mRNA vaccine for older adults (SP0256), which lays the groundwork for investigating a combination vaccine targeting multiple pathogens, such as Respiratory Syncytial Virus, human Metapneumovirus, and Parainfluenza virus, in older adults.
The event will also feature the initial data from the mRNA Flu Quadrivalent vaccine and promising results from the next-generation neuraminidase-encoding mRNA Flu vaccine, supporting further development of this innovative program.
Sanofi will present the latest data from the Phase I/II pediatric pneumococcal vaccine program (SP0202), developed in collaboration with SK Biosciences. Positive safety and immunogenicity results will be shared for the first PCV21 vaccine, designed to enhance protection against pneumococcal disease using an innovative carrier that expands the serotype compositions. The Phase III initiation of the pediatric pneumococcal vaccine is planned for the first half of 2024, with expected approval submission in 2027.
The event will also highlight the exceptional profile of MenQuadfi and its unique ready-to-use syringe in combating meningitis. Sanofi has scheduled the submission of MenQuadfi, the first and only ready-to-use syringe, to the FDA in July 2023, with a projected launch in 2024. Positive Phase I/II results from the Men B program (SP0230) will be presented, supporting the progression to the next phase of development.
Sanofi will introduce initial data from its multi-antigen chlamydia vaccine candidate, which is set to enter Phase I/II trials in early 2024. Additionally, preclinical results will be shared for its therapeutic mRNA vaccine candidate targeting acne, which is expected to advance into Phase I/II trials in the second half of 2023.
Overall, this investor event will showcase Sanofi’s robust vaccines pipeline and its commitment to driving innovation in the field of immunization, as the company continues to address unmet medical needs and improve global health.
